FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207675> ?p ?o ?g. }

• W4387207675 endingPage "S162" @default.
• W4387207675 startingPage "S162" @default.
• W4387207675 abstract "Patients with R/R acute leukemia after allogeneic hematopoietic cell transplant (alloHCT) have a dismal prognosis with 3-year survival rates of < 20%. To improve outcomes, innovative targeted forms of organ sparing radiotherapy, such as tumor-specific RIT and TMLI, are needed to dose escalate with acceptable toxicities, especially in patients ≥ age 60 years who cannot tolerate total body irradiation (TBI) / myeloablative regimens and who have a poor prognosis. CD25 is an ideal RIT target given its expression in acute leukemias, association with poor prognosis, and expression by leukemia stem cells. In this phase I trial (NCT05139004) we hypothesized that combining dose escalated 90Y-anti-CD25 RIT with fixed dose TMLI 12 Gy, fludarabine (flu), and melphalan (mel) in patients with R/R disease is safe and associated with acceptable toxicities.The primary objective of this trial is to determine the maximum tolerated dose and recommended phase 2 dose of 90Y-anti-CD25 Mab (Day -15) with 12 Gy TMLI (1.5 Gy twice a day, days -8 to -5), flu (30 mg/m2/d days -5 to -2), and mel (100 mg/m2, day -2) in patients ≥ 60 years old or with a HCT-comorbidity index ≥ 2 and with R/R AML, ALL or myelodysplastic syndrome (MDS) scheduled to undergo alloHCT from a matched donor. TMLI mean organ dose constraints for kidney, lung and liver were 4 Gy. Planned dose levels of 90Y-anti-CD25 were 0.3, 0.4, and 0.5 mCi/kg. 111In-anti-CD25 (5 mCi) was co-infused followed by serial nuclear scans to assess dosimetry and biodistribution.To date 5 patients (ages 31-74) with R/R AML have been treated. Marrow and circulating blasts ranged from 10-36% and 9-44%, respectively. For the 3 patients at 0.3 mCi/kg, follow-up ranged from 89-191+ days. 90Y/111In-anti-CD25 nuclear scans demonstrated persistent uptake in bone out to 144 hours, which was associated with a decline in circulating blasts. After combined RIT and TMLI, mean doses (Gy) to lungs ranged from 5.7-6.5, to kidneys from 7.5-8.2 and to liver from 7.2-11.6. No dose-limiting toxicities (DLT) were observed. All 3 patients achieved CR on day +30 bone marrow biopsies and 2 remained in CR on day +90 biopsies. Two patients have recently been treated at the 0.4 mCi/kg dose level. The results of patients treated at the higher dose levels will be provided.Dose escalation by adding 90Y-anti-CD25 RIT at 0.3 mCi/kg to 12 Gy TMLI was safe, including in older patients, with no dose-limiting toxicities, mean critical organ doses lower than conventional myeloablative TBI, and encouraging response rates. The toxicity profile and dose estimates at 0.3 mCi/kg predict that the planned higher dose levels will also be feasible with acceptable toxicities. RIT and TMLI are complementary and when combined address the limitations of each modality. Combining these targeted therapies may be a superior strategy to intensify dose to leukemia compared to dose escalation of either modality alone." @default.
• W4387207675 created "2023-09-30" @default.
• W4387207675 creator A5000419970 @default.
• W4387207675 creator A5003439933 @default.
• W4387207675 creator A5004337476 @default.
• W4387207675 creator A5008771425 @default.
• W4387207675 creator A5016834515 @default.
• W4387207675 creator A5020684790 @default.
• W4387207675 creator A5023162628 @default.
• W4387207675 creator A5034028155 @default.
• W4387207675 creator A5040357722 @default.
• W4387207675 creator A5044247994 @default.
• W4387207675 creator A5062118956 @default.
• W4387207675 creator A5065052780 @default.
• W4387207675 creator A5065938090 @default.
• W4387207675 creator A5070193149 @default.
• W4387207675 creator A5071244558 @default.
• W4387207675 creator A5081883519 @default.
• W4387207675 creator A5089824277 @default.
• W4387207675 creator A5091810662 @default.
• W4387207675 creator A5092972813 @default.
• W4387207675 date "2023-10-01" @default.
• W4387207675 modified "2023-10-04" @default.
• W4387207675 title "First-in-Human Phase I Trial Combining Biologically Guided Radioimmunotherapy (RIT) Using a 90Y-Anti-CD25 Monoclonal Antibody (Mab) with CT-guided Total Marrow and Lymphoid Irradiation (TMLI) in Relapsed and Refractory (R/R) Acute Leukemia" @default.
• W4387207675 doi "https://doi.org/10.1016/j.ijrobp.2023.06.256" @default.
• W4387207675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784406" @default.
• W4387207675 hasPublicationYear "2023" @default.
• W4387207675 type Work @default.
• W4387207675 citedByCount "0" @default.
• W4387207675 crossrefType "journal-article" @default.
• W4387207675 hasAuthorship W4387207675A5000419970 @default.
• W4387207675 hasAuthorship W4387207675A5003439933 @default.
• W4387207675 hasAuthorship W4387207675A5004337476 @default.
• W4387207675 hasAuthorship W4387207675A5008771425 @default.
• W4387207675 hasAuthorship W4387207675A5016834515 @default.
• W4387207675 hasAuthorship W4387207675A5020684790 @default.
• W4387207675 hasAuthorship W4387207675A5023162628 @default.
• W4387207675 hasAuthorship W4387207675A5034028155 @default.
• W4387207675 hasAuthorship W4387207675A5040357722 @default.
• W4387207675 hasAuthorship W4387207675A5044247994 @default.
• W4387207675 hasAuthorship W4387207675A5062118956 @default.
• W4387207675 hasAuthorship W4387207675A5065052780 @default.
• W4387207675 hasAuthorship W4387207675A5065938090 @default.
• W4387207675 hasAuthorship W4387207675A5070193149 @default.
• W4387207675 hasAuthorship W4387207675A5071244558 @default.
• W4387207675 hasAuthorship W4387207675A5081883519 @default.
• W4387207675 hasAuthorship W4387207675A5089824277 @default.
• W4387207675 hasAuthorship W4387207675A5091810662 @default.
• W4387207675 hasAuthorship W4387207675A5092972813 @default.
• W4387207675 hasConcept C126322002 @default.
• W4387207675 hasConcept C141071460 @default.
• W4387207675 hasConcept C143998085 @default.
• W4387207675 hasConcept C159654299 @default.
• W4387207675 hasConcept C203014093 @default.
• W4387207675 hasConcept C2776090121 @default.
• W4387207675 hasConcept C2776146153 @default.
• W4387207675 hasConcept C2776694085 @default.
• W4387207675 hasConcept C2776755627 @default.
• W4387207675 hasConcept C2778880498 @default.
• W4387207675 hasConcept C2779263901 @default.
• W4387207675 hasConcept C542903549 @default.
• W4387207675 hasConcept C71924100 @default.
• W4387207675 hasConcept C79484868 @default.
• W4387207675 hasConcept C8891405 @default.
• W4387207675 hasConcept C90924648 @default.
• W4387207675 hasConceptScore W4387207675C126322002 @default.
• W4387207675 hasConceptScore W4387207675C141071460 @default.
• W4387207675 hasConceptScore W4387207675C143998085 @default.
• W4387207675 hasConceptScore W4387207675C159654299 @default.
• W4387207675 hasConceptScore W4387207675C203014093 @default.
• W4387207675 hasConceptScore W4387207675C2776090121 @default.
• W4387207675 hasConceptScore W4387207675C2776146153 @default.
• W4387207675 hasConceptScore W4387207675C2776694085 @default.
• W4387207675 hasConceptScore W4387207675C2776755627 @default.
• W4387207675 hasConceptScore W4387207675C2778880498 @default.
• W4387207675 hasConceptScore W4387207675C2779263901 @default.
• W4387207675 hasConceptScore W4387207675C542903549 @default.
• W4387207675 hasConceptScore W4387207675C71924100 @default.
• W4387207675 hasConceptScore W4387207675C79484868 @default.
• W4387207675 hasConceptScore W4387207675C8891405 @default.
• W4387207675 hasConceptScore W4387207675C90924648 @default.
• W4387207675 hasIssue "2" @default.
• W4387207675 hasLocation W43872076751 @default.
• W4387207675 hasLocation W43872076752 @default.
• W4387207675 hasOpenAccess W4387207675 @default.
• W4387207675 hasPrimaryLocation W43872076751 @default.
• W4387207675 hasRelatedWork W2092854200 @default.
• W4387207675 hasRelatedWork W2287774911 @default.
• W4387207675 hasRelatedWork W2556838688 @default.
• W4387207675 hasRelatedWork W2580584975 @default.
• W4387207675 hasRelatedWork W2587399432 @default.
• W4387207675 hasRelatedWork W2914015933 @default.
• W4387207675 hasRelatedWork W2936466505 @default.
• W4387207675 hasRelatedWork W2969981550 @default.
• W4387207675 hasRelatedWork W2975088841 @default.
• W4387207675 hasRelatedWork W4387207675 @default.
• W4387207675 hasVolume "117" @default.
• W4387207675 isParatext "false" @default.

• next